G-CSF employing neuroprotection study for ischemic stroke -Phase 2 clinical trial-(GENESIS-2) - G-CSF employing neuroprotection study for ischemic stroke -Phase 2 clinical trial-(GENESIS-2)

Tokai University, School of Medicine, Division of Neurology, Department of Internal Medicine.0 sites100 target enrollmentDecember 1, 2011

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: acute cerebral infarction
Sponsor: Tokai University, School of Medicine, Division of Neurology, Department of Internal Medicine.
Enrollment: 100
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

December 1, 2011

End Date

October 12, 2014

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Tokai University, School of Medicine, Division of Neurology, Department of Internal Medicine.

•1\.Splenomegaly or splenic lesions on echo. 2\.Leukocytosis more than 15000/mm3 3\.Past history of G\-CSF treatment. 4\.Plan for percutaneous angiography or bypass operations. 5\.Difficult to perform MRI. 6\.Past histries of symptomatic intracranial hemorrhage, bleeding tendency or coagulating disorders. 7\.Hyper reactivity to G\-CSF. 8\.Congestive heart failure or uncontrollable angina. 9\.Thrombocytopenia(less than 140000/mm3\) 10\.Liver dysfunction(AST(GOT),ALT(GPT) more than 100 IU/L) 11\.Renal dysfunction (creatinine 1\.5mg/dl and more) 12\.Difficult to continue this trial due to social problems, etc. 13\.Join other clinical trials. 14\.Inappropriate to enroll in this trial by the judgment of the doctor.